Table S1 Comparison of adult height and height improvement in treated and untreated IGHD patients in male

Group	Treated with rhGH	Untreated with rhGH	P
N	65	72	
Age (years)	18.40±1.52	19.20±2.06	0.01
Adult Height (cm)	169.74±4.98	167.65±5.79	0.03
Adult Height SDS	-0.45 (-0.78 to 0.05)	-0.53 (-1.49 to -0.24)	0.03
Follow up duration (years)	5.06 (4.26-6.21)	5.19 (4.56-7.79)	0.22
Treatment duration (years)	1.50 (0.55-2.50)	-	0.45
Height SDS gain	2.10 (1.69-2.61)	1.76 (0.99-2.62)	0.048

SDS: standard deviation score; IGHD: idiopathic growth hormone deficiency; rhGH: recombinant human growth hormone. $P<0.05$ is considered to be statistically significant.

Table S2 Comparison of adult height and height improvement in treated and untreated IGHD patients in female

Group	Treated with rhGH	Untreated with rhGH	P
N	19	13	
Age (years)	18.76±0.95	19.69±1.17	0.07
Adult Height (cm)	157.95±4.45	153.88±5.55	0.03
Adult Height SDS	-0.39 (-0.94 to 0.17)	-1.31 (-1.87 to -0.02)	0.03
Follow up duration (years)	6.51 (5.30-8.26)	8.29 (4.80-9.21)	0.65
Treatment duration (years)	1.55 (0.75-1.88)	-	
Height SDS gain	2.08 (1.77-2.81)	1.72 (0.87-2.06)	0.046

SDS: standard deviation score; IGHD: idiopathic growth hormone deficiency; rhGH: recombinant human growth hormone. $P<0.05$ is considered to be statistically significant.

Table S3 Independent association between rhGH treatment and growth outcome in IGHD

Growth outcome	β (95% CI)	P value
Height SDS gain		
Treated with rhGH		
No	0	
Yes	0.40 (0.11, 0.68)	0.007
Adult Height SDS		
Treated with rhGH		
No	0	
Yes	0.41 (0.14, 0.69)	0.003

SDS: standard deviation score; rhGH: recombinant human growth hormone. Adjustment variables: age, sex, birth weight, birth length, height and Peak GH. $P<0.05$ is considered to be statistically significant.